Methods: We measured CSF amyloid β (Aβ)42 and Aβ40, neurofilament light chain protein (NfL), total(t)-tau and phosphorylated(p)-tau in healthy controls (n = 38) and subjects with cognitive disorders including NPH (n = 66), Alzheimer’s disease (AD) (n = 60), vascular dementia (n = 30), frontotemporal dementia spectrum (FTD) (n = 80), and dementia with Lewy bodies (n = 35). The gene discussed is MAPT; the disease is Cognitive impairment.